Depression doesn’t just affect how people feel – it affects how they function. For those living with major depressive disorder (MDD), sticking to a daily treatment plan can be an uphill battle.
In clinical trials, this presents a serious obstacle: missed doses and inconsistent engagement can undermine the results and slow progress toward better therapies. That’s why researchers are turning to digital medication adherence solutions – tools designed to track behavior and actively support patients in real time.
These technologies offer a more innovative and responsive way to keep patients engaged and ensure the data collected reflects the true impact of the treatment being studied.
Depression and its impact
Depression is one of the most disabling mental health disorders in the world. Affecting around 5% of adults globally, its prevalence surged during the Covid pandemic, particularly among younger individuals and women
Despite public awareness, depression is still often misunderstood or downplayed. The DSM-5 defines a major depressive episode as lasting at least two weeks, characterised by low mood or a loss of interest in daily activities, alongside other symptoms such as fatigue, sleep disturbances, difficulty concentrating, and poor self-worth.
The effects can be profound. Depression can disrupt work, relationships, and physical health, and in severe cases, it can lead to suicide – a tragedy that claims more than 700,000 lives annually. This underscores the critical need to understand how to better support patients through treatment and recovery, including within clinical trials.
Challenges of depression and medication adherence in clinical trials
Clinical trials for antidepressant therapies face complex hurdles, particularly regarding medication adherence. Data from trials using electronic monitoring have shown that adherence to antidepressants is especially poor, with nearly 50% of participants discontinuing treatment within three months.
This isn’t surprising. The very nature of major depressive disorder (MDD) can compromise a person’s ability to follow treatment plans. Cognitive symptoms – such as trouble concentrating, indecision, or memory lapses – make it difficult for some individuals to take medication consistently. Others may lack the motivation or emotional energy to engage in structured routines.
Furthermore, rumination – a common trait in depression – can cause patients to monitor their symptoms excessively, leading them to doubt the medication’s efficacy early in treatment. This often results in missed doses or complete withdrawal from the trial.
Outside of clinical settings, the challenge remains. One study found that nearly 28% of patients prescribed antidepressants either never started the medication or stopped after just one prescription.
Improving adherence in trials
Recognising these unique challenges, researchers have explored ways to improve adherence in depression trials. Interventions – including digital reminders, education, and behavioural support – have shown promise. One review found that targeted strategies helped improve short and medium-term adherence among adults with depressive disorders.
However, the success of any intervention depends on the quality of data available. In routine care or clinical research, knowing exactly when and how often medication is taken allows for more informed decisions. Without this insight, it’s difficult to assess treatment efficacy or intervene appropriately when adherence falters.
This highlights the importance of embracing robust monitoring tools, especially in populations vulnerable to inconsistency, such as individuals with MDD.
Barriers to measuring depression and medication adherence accurately
Tracking adherence in depression trials brings its own set of complications. Traditional methods, like patient self-reporting, are vulnerable to inaccuracies. People may forget, underreport, or intentionally misstate their medication use due to stigma or fear of judgement.
Additionally, the placebo effect presents another challenge. Depression trials often have strong and variable placebo responses, which can obscure true treatment effects. It’s even harder to interpret outcomes with confidence without accurate adherence data.
These challenges point to a clear need for more objective, consistent ways to monitor medication use – tools that bypass self-reporting limitations and produce cleaner, more reliable datasets.
The wider impact of depression on trials
Significantly, the impact of depression extends beyond trials focused solely on mental health. MDD is a common comorbidity in many chronic illnesses, including cardiovascular disease, autoimmune disorders, and neurological conditions.
In these trials, participants with undiagnosed or unmanaged depression may still exhibit poor adherence, which can quietly compromise study results. Yet, identifying these individuals isn’t always easy. Symptom overlap, such as fatigue or cognitive fog, can make a diagnosis of depression challenging in comorbid populations.
A study exploring psychiatric comorbidities in immune-mediated diseases found that 40.1% of participants met diagnostic criteria for depression, but one-third were undiagnosed. This highlights a blind spot in many trials: the hidden presence of depression among participants and its potential to reduce adherence and affect data integrity.
The role of technology in improving adherence
Whether depression is the focus of a study or a hidden factor within it, it’s essential to use tools that offer accurate, consistent monitoring of medication intake. Modern digital adherence solutions – including smart packaging, mobile apps, and connected devices – can help researchers and clinicians track real-time medication behavior.
Unlike self-reporting, these technologies provide objective insights that can be used to support both patients and research quality. They also enable timely interventions if someone begins to miss doses, offering an opportunity to re-engage them before dropout or treatment failure occurs.
Many of these tools are also designed to support patients with cognitive or motivational difficulties, making them particularly well-suited for MDD populations. Features like simplified interfaces, reminders, and motivational feedback can help reinforce medication routines and build healthier habits over time.
By integrating these approaches into mental health research, we can create more scientifically rigorous studies and more supportive of the patients involved. And with stronger data and more informed decision-making, we move closer to developing truly effective treatments for a condition affecting many lives.
Ellen Diamond, a psychology graduate from the University of Hertfordshire, has a keen interest in the fields of mental health, wellness, and lifestyle.
